
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7497652/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage. Immunity, 2008, 29, 391-403.	14.3	637
2	The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nature Immunology, 2012, 13, 29-34.	14.5	195
3	Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses. Nature Immunology, 2007, 8, 84-91.	14.5	156
4	Intrathymic proliferation wave essential for Vα14 ⁺ natural killer T cell development depends on c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8641-8646.	7.1	100
5	COVIDâ€19 infection in patients with sickle cell disease. British Journal of Haematology, 2020, 189, 851-852.	2.5	90
6	Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase. Journal of Biological Chemistry, 2002, 277, 39334-39342.	3.4	81
7	Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. Journal of Experimental Medicine, 2009, 206, 707-719.	8.5	81
8	Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. Biochemical Pharmacology, 2014, 88, 150-157.	4.4	60
9	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Advances, 2021, 5, 207-215.	5.2	59
10	HIP-55 Is Important for T-Cell Proliferation, Cytokine Production, and Immune Responses. Molecular and Cellular Biology, 2005, 25, 6869-6878.	2.3	56
11	The SH3 Domain-containing Adaptor HIP-55 Mediates c-Jun N-terminal Kinase Activation in T Cell Receptor Signaling. Journal of Biological Chemistry, 2003, 278, 52195-52202.	3.4	51
12	Actin-Binding Protein 1 Regulates B Cell Receptor-Mediated Antigen Processing and Presentation in Response to B Cell Receptor Activation. Journal of Immunology, 2008, 180, 6685-6695.	0.8	51
13	Mitochondria as therapeutic targets for cancer stem cells. World Journal of Stem Cells, 2015, 7, 418.	2.8	48
14	APOL1 , α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica, 2017, 102, e1-e6.	3.5	47
15	Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Research, 2005, 33, 2769-2780.	14.5	41
16	ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Research, 2004, 32, 1232-1241.	14.5	38
17	Characterization of opioid use in sickle cell disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 479-486.	1.9	37
18	Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths. International Journal of Pharmaceutics, 2014, 473, 375-383.	5.2	34

#	Article	IF	CITATIONS
19	Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Advances, 2020, 4, 1978-1986.	5.2	28
20	Patterns of opioid use in sickle cell disease. American Journal of Hematology, 2016, 91, 1102-1106.	4.1	24
21	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Human Genetics, 2015, 134, 895-904.	3.8	20
22	HMOX1 and acute kidney injury in sickle cell anemia. Blood, 2018, 132, 1621-1625.	1.4	20
23	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vasoâ€occlusive Pain Crises in Patients with Sickle Cell Disease. Pharmacotherapy, 2020, 40, 535-543.	2.6	19
24	Systematic Review of Voxelotor: A Firstâ€inâ€Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. Pharmacotherapy, 2020, 40, 525-534.	2.6	17
25	Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage. Molecular Cancer Therapeutics, 2012, 11, 2311-2320.	4.1	16
26	Risk factors for vitamin D deficiency in sickle cell disease. British Journal of Haematology, 2018, 181, 828-835.	2.5	16
27	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6â€year populationâ€based cohort study. British Journal of Haematology, 2018, 182, 259-270.	2.5	16
28	Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease. Annals of Pharmacotherapy, 2017, 51, 357-358.	1.9	15
29	Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure. PLoS ONE, 2013, 8, e71268.	2.5	14
30	Hemolysis and hemolysisâ€related complications in females vs. males with sickle cell disease. American Journal of Hematology, 2018, 93, E376-E380.	4.1	14
31	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a sixâ€year populationâ€based cohort analysis. British Journal of Haematology, 2019, 185, 116-127.	2.5	14
32	Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer. Phytomedicine, 2021, 91, 153674.	5.3	13
33	Platelets decline during <scp>V</scp> asoâ€occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. American Journal of Hematology, 2015, 90, E228-9.	4.1	12
34	The morbidity and mortality of end stage renal disease in sickle cell disease. American Journal of Hematology, 2019, 94, E138-E141.	4.1	11
35	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1469-1475.	2.8	10
36	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. Pharmacotherapy, 2016, 36, 1166-1172.	2.6	10

#	Article	IF	CITATIONS
37	Erythropoiesisâ€stimulating agents in sickle cell anaemia. British Journal of Haematology, 2018, 182, 602-605.	2.5	9
38	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. Journal of Cancer Survivorship, 2020, 14, 294-304.	2.9	9
39	Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. American Journal of Health-System Pharmacy, 2016, 73, 947-948.	1.0	8
40	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6â€Year Propensity Score–Matched Cohort Study. Pharmacotherapy, 2019, 39, 55-66.	2.6	8
41	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. Pharmacotherapy, 2015, 35, 696-700.	2.6	7
42	Program expansion of a day hospital dedicated to manage sickle cell pain. American Journal of Hematology, 2018, 93, E20-E21.	4.1	7
43	"Maximum tolerated dose―vs "fixed lowâ€dose―hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 2019, 94, E112-E115.	4.1	7
44	Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. British Journal of Haematology, 2021, 194, 767-778.	2.5	6
45	Use of metformin in patients with sickle cell disease. American Journal of Hematology, 2019, 94, E13-E15.	4.1	5
46	Voxelotor and albuminuria in adults with sickle cell anaemia. British Journal of Haematology, 2022, , .	2.5	5
47	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. Haematologica, 2017, 102, e282-e284.	3.5	4
48	Kidney ultrasound findings according to kidney function in sickle cell anemia. American Journal of Hematology, 2019, 94, E288-E291.	4.1	4
49	Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children. Pakistan Journal of Medical Sciences, 1969, 30, 519-24.	0.6	3
50	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. British Journal of Haematology, 2020, 191, e70-e72.	2.5	3
51	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. Blood, 2015, 126, 3400-3400.	1.4	3
52	Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. Haematologica, 2021, 106, 1745-1748.	3.5	3
53	Effects of reninâ€angiotensin blockade and APOL1 on kidney function in sickle cell disease. EJHaem, 2021, 2, 483-484.	1.0	2
54	Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia. Blood, 2019, 134, 3558-3558.	1.4	2

#	Article	lF	CITATIONS
55	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sβ+â€thalassemia sickle cell disease. American Journal of Hematology, 2016, 91, E316-7.	4.1	1
56	Reply to <scp>R</scp> uan <scp>X</scp> et al: "A comment on pattern of opioid use in sickle cell disease― American Journal of Hematology, 2017, 92, E43.	4.1	1
57	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. American Journal of Hematology, 2019, 94, E5-E7.	4.1	1
58	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. JAMA Network Open, 2021, 4, e2118410.	5.9	1
59	Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. Blood, 2021, 138, 2051-2051.	1.4	1
60	Defining and Predicting Rapid Egfr Decline in Sickle Cell Disease. Blood, 2021, 138, 122-122.	1.4	1
61	Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center. Blood, 2020, 136, 22-23.	1.4	1
62	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i>etÂal</i> . British Journal of Haematology, 2019, 186, 782-783.	2.5	0
63	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. Obesity Surgery, 2019, 29, 3762-3764.	2.1	0
64	Evaluation of pointâ€of are International Normalized Ratio in sickle cell disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12533.	2.3	0
65	Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. Annals of Pharmacotherapy, 2022, 56, 222-223.	1.9	0
66	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12â€year single health systemâ€based cohort analysis. EJHaem, 2021, 2, 97-101.	1.0	0
67	Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. Blood, 2015, 126, 3413-3413.	1.4	0
68	Risk Factors for Kidney Disease in Hb SC and Hb Sβ+-Thalassemia Sickle Cell Disease. Blood, 2019, 134, 2299-2299.	1.4	0
69	Impact of Intravenous Opioid Shortage on Managing Pain Crisis in Sickle Cell Disease. Blood, 2019, 134, 3390-3390.	1.4	0
70	Implementation of a Standard Order Set at a Sickle Cell Acute Care Observation Unit. Blood, 2019, 134, 3396-3396.	1.4	0
71	Genotype-Guided vs Clinically-Guided Stable Warfarin Dose Prediction and Stable Dose Establishment In A Predominantly Non-European Ancestry Population. Expert Review of Precision Medicine and Drug Development, 2021, 6, 375-379.	0.7	0
72	Clinical and Biomarker Predictors for Avascular Necrosis in Sickle Cell Disease. Blood, 2021, 138, 3091-3091.	1.4	0

#	Article	IF	CITATIONS
73	HIF-Mediated and Non-HIF-Mediated Differential Gene Expressions in Sickle Cell Reticulocyte and Their Impact on Clinical Manifestations. Blood, 2021, 138, 950-950.	1.4	Ο
74	Naloxone Use for Opioid Reversal in Patients with Sickle Cell Disease. Blood, 2021, 138, 2038-2038.	1.4	0
75	Haptoglobin 1-1 Isoform Predicts Higher Serum Haptoglobin Concentration and Lower Multiorgan Failure Risk in Sickle Cell Disease. Blood, 2021, 138, 3095-3095.	1.4	Ο
76	Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. Blood, 2020, 136, 21-22.	1.4	0
77	Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. Blood, 2020, 136, 18-19.	1.4	Ο
78	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. Blood, 2020, 136, 34-35.	1.4	0